Relapsed or Refractory Multiple Myeloma: Prospective Study with Bortezomib, Non-Pegylated Liposomal Doxorubicin and Dexamethason (PAD Regimen)

被引：0
|
作者：
Falcone, Antonietta Pia [1 ]
Sanpaolo, Grazia [1 ]
Rossi, Giovanni [2 ]
Bodenizza, Carlo [1 ]
Carella, Angelo Michele [3 ]
Dell' Olio, Matte [1 ]
Greco, Michele Mario [4 ]
La Sala, Antonio [1 ]
Mantuano, Saverio [1 ]
Melillo, Lorella [5 ]
Merla, Emanuela [4 ]
Nobile, Michele [1 ]
Scalzulli, Potito R. [6 ]
Capalbo, Silvana [7 ]
Cascavilla, Nicola [2 ]
机构：
[1] IRCCS Casa Sollievo della Sofferenza Hosp, Dept Hematol & Stem Cell Transplantat, San Giovanni Rotondo, Italy
[2] IRCCS, Hematol & Stem Cell Transplantat Unit, San Giovanni Rotondo, Italy
[3] IRCCS Casa Sollievo della Sofferenza Hosp, Hematol & Stem Cell Transplantat Unit, San Giovanni Rotondo, Italy
[4] IRCCS Casa Sollievo Sofferenza, Hematol & Stem Cell Transplantat Unit, San Giovanni Rotondo, Italy
[5] IRCCS, Hematol & Stem Cell Unit, San Giovanni Rotondo, Italy
[6] IRCCS Casa Sollievo Sofferenza, Hematol Unit, San Giovanni Rotondo, Italy
[7] Osped Riuniti Azienda Osped Univ, Foggia, Italy
来源：
BLOOD | 2012年 / 120卷 / 21期
关键词：
D O I：
10.1182/blood.V120.21.5032.5032
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
5032
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Bortezomib in combination with pegylated liposomal doxorubicin for the treatment of multiple myeloma
    Manochakian, Rarni
    Miller, Kena C.
    Chanan-Khan, Asher Alban
    CLINICAL LYMPHOMA & MYELOMA, 2007, 7 (04): : 266 - 271
  • [22] Pegylated Liposomal Doxorubicin A Review of its Use in the Treatment of Relapsed or Refractory Multiple Myeloma
    Plosker, Greg L.
    DRUGS, 2008, 68 (17) : 2535 - 2551
  • [23] A Phase II Study of Carfilzomib, Pegylated Liposomal Doxorubicin, and Dexamethasone [CDD] for Relapsed or Refractory Multiple Myeloma
    Fiala, Mark
    Keller, Jesse
    Sekhar, Jeevan
    Ceriotti, Connie
    Abboud, Camille
    DiPersio, John
    Tomasson, Michael
    Wildes, Tanya
    Stockerl-Goldstein, Keith
    Vij, Ravi
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (01): : E56 - E56
  • [24] A retrospective review of pegylated liposomal doxorubicin (PLD), bortezomib, and dexamethasone (DVD) for relapsed or refractory (R/R) multiple myeloma (MM)
    Waterman, G. N.
    Yellin, O.
    Swift, R. A.
    Hilger, J.
    Berenson, J. R.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [25] COMBINATION OF THALIDOMIDE, PEGYLATED LIPOSOMAL DOXORUBICIN, DEXAMETHASONE AND BORTEZOMIB (THADD-V) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: RESULTS OF A PHASE II STUDY
    Offidani, M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 153 - 153
  • [26] Final Overall Survival Results of a Randomized Trial Comparing Bortezomib Plus Pegylated Liposomal Doxorubicin with Bortezomib Alone in Subjects with Relapsed or Refractory Multiple Myeloma
    Orlowski, Robert Z.
    Nagler, Arnon
    Sonneveld, Pieter
    Blade, Joan
    Hajek, Roman
    Spencer, Andrew
    Robak, Tadeusz
    Dmoszynska, Anna
    Horvath, Noemi
    Spicka, Ivan
    Sutherland, Heather J.
    Suvorov, Alexander
    Xiu, Liang
    Parekh, Trilok V.
    San Miguel, Jesus
    BLOOD, 2014, 124 (21)
  • [27] Safety and efficacy of pomalidomide, dexamethasone and pegylated liposomal doxorubicin for patients with relapsed or refractory multiple myeloma
    Cohen, Alexa
    Spektor, Tanya M.
    Stampleman, Laura
    Bessudo, Alberto
    Rosen, Peter J.
    Klein, Leonard M.
    Woliver, Thomas
    Flam, Marshall
    Eshaghian, Shahrooz
    Nassir, Youram
    Maluso, Tina
    Swift, Regina A.
    Vescio, Robert
    Berenson, James R.
    BRITISH JOURNAL OF HAEMATOLOGY, 2018, 180 (01) : 60 - 70
  • [28] Effect of the combination of pegylated liposomal doxorubicin and bortezomib on time to progression (TTP) and overall survival of patients with relapsed/refractory multiple myeloma compared with bortezomib alone
    Harousseau, J. L.
    Nagler, A.
    Sonneveld, P.
    Blade, J.
    Hajek, R.
    Spencer, A.
    Robak, T.
    Xiu, L.
    Zhuang, S. H.
    Orlowski, R. Z.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [29] Final overall survival results of a randomized trial comparing bortezomib plus pegylated liposomal doxorubicin with bortezomib alone in patients with relapsed or refractory multiple myeloma
    Orlowski, Robert Z.
    Nagler, Arnon
    Sonneveld, Pieter
    Blade, Joan
    Hajek, Roman
    Spencer, Andrew
    Robak, Tadeusz
    Dmoszynska, Anna
    Horvath, Noemi
    Spicka, Ivan
    Sutherland, Heather J.
    Suvorov, Alexander N.
    Xiu, Liang
    Cakana, Andrew
    Parekh, Trilok
    San-Miguel, Jesus F.
    CANCER, 2016, 122 (13) : 2050 - 2056
  • [30] Bortezomib in combination with pegylated liposomal doxorubicin and thalidomide is an effective steroid independent salvage regimen for patients with relapsed or refractory multiple myeloma: results of a phase II clinical trial
    Chanan-Khan, Asher
    Miller, Kena C.
    Musial, Laurie
    Padmanabhan, Swaminathan
    Yu, Jihnhee
    Ailawadhi, Sikander
    Sher, Taimur
    Mohr, Alice
    Bernstein, Zale P.
    Barcos, Maurice
    Patel, Mehul
    Iancu, Dan
    Lee, Kelvin
    Czuczman, Myron S.
    LEUKEMIA & LYMPHOMA, 2009, 50 (07) : 1096 - 1101
12345